{"id":449269,"date":"2021-03-03T07:03:12","date_gmt":"2021-03-03T12:03:12","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=449269"},"modified":"2021-03-03T07:03:12","modified_gmt":"2021-03-03T12:03:12","slug":"kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\/","title":{"rendered":"Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S."},"content":{"rendered":"
\n

\n Transaction Furthers Kamada\u2019s Strategic Objective to Evolve into a <\/em>
\n Fully Integrated Specialty Plasma Company<\/em>
\n \n <\/p>\n

\n Kamada is Already Actively Engaged in the Expansion of <\/em>
\n the Center\u2019s Collection Capacity; Planning to Open Additional Plasma Collection Centers <\/em>\n <\/p>\n

REHOVOT, Israel, March 03, 2021 (GLOBE NEWSWIRE) — Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today updated that it has completed the previously announced acquisition of the FDA licensed plasma collection center and certain related rights and assets from the privately-held Blood and Plasma Research, Inc (B&PR) of Beaumont, TX, USA.<\/p>\n

\u201cThis acquisition furthers our strategic goal of becoming a fully integrated specialty plasma company,\u201d said Amir London, CEO of Kamada. \u201cWe are already actively engaged in the expansion of the hyperimmune plasma collection capacity of the center and we plan on leveraging its FDA license to open additional centers in the U.S. We are committed to growing our hyperimmune IgG portfolio and believe this acquisition is a significant strategic step in this direction.\u201d<\/p>\n

The acquisition for a total consideration of approximately $1.66 million, was consummated through Kamada Plasma LLC, a newly formed wholly owned subsidiary of Kamada, which will operate the Company\u2019s plasma collection activity in the U.S.<\/p>\n

Kamada retained Jackson Walker LLP as legal advisors for this acquisition.<\/p>\n

\n About Kamada<\/strong>
\n
Kamada Ltd. (the \u201cCompany\u201d) is a global specialty plasma-derived biopharmaceutical company with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The Company\u2019s strategy is focused on driving profitable growth from its current commercial products, its plasma-derived development pipeline and its manufacturing expertise, while evolving into a vertically integrated plasma-derived company. The Company\u2019s two leading commercial products are GLASSIA\u00ae and KEDRRAB\u00ae. GLASSIA was the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the FDA. The Company markets GLASSIA in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited (“Takeda”) and in other countries through local distributors. Pursuant to an agreement with Takeda, the Company will continue to produce GLASSIA for Takeda through 2021 and Takeda will initiate its own production of GLASSIA for the U.S. market in 2021, at which point Takeda will commence payment of royalties to the Company until 2040. KEDRAB is an FDA approved anti-rabies immune globulin (Human) for post-exposure prophylaxis treatment. KEDRAB is being marketed in the U.S. through a strategic partnership with Kedrion S.p.A. The Company has additional four plasma-derived products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has two leading development programs; a plasma-derived hyperimmune immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19) and an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added nine biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel between the years 2022 and 2025. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company\u2019s lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.<\/p>\n

\n Cautionary Note Regarding Forward-Looking Statements<\/strong>
\n
This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: 1) Kamada’s expectations regarding the benefits of the acquisition, including the acquisition being a significant strategic step to becoming a fully integrated specialty plasma company, 2) Kamada\u2019s plan to significantly expand its hyperimmune plasma collection capacity by investing in B&PR\u2019s center; 3) Kamada\u2019s ability to leveraging B&PR\u2019s FDA license to open additional centers in the U.S.; and 4) Kamada\u2019s commitment to growing its hyperimmune IgG portfolio.\u00a0\u00a0 Forward-looking statements are based on Kamada\u2019s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, Kamada\u2019s inability to achieve the benefits of the acquisition, including inability to leverage B&PR\u2019s FDA license to open additional centers in the U.S., and the impact of general economic, industry or political conditions in the U.S., Israel or otherwise. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.<\/p>\n

\n CONTACTS:<\/strong>
\n
Chaime Orlev
Chief Financial Officer
IR@kamada.com<\/a>\u00a0<\/p>\n

Bob Yedid
LifeSci Advisors, LLC
646-597-6989
Bob@LifeSciAdvisors.com<\/a>\u00a0<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Transaction Furthers Kamada\u2019s Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company Kamada is Already Actively Engaged in the Expansion of the Center\u2019s Collection Capacity; Planning to Open Additional Plasma Collection Centers REHOVOT, Israel, March 03, 2021 (GLOBE NEWSWIRE) — Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today updated that it has completed the previously announced acquisition of the FDA licensed plasma collection center and certain related rights and assets from the privately-held Blood and Plasma Research, Inc (B&PR) of Beaumont, TX, USA. \u201cThis acquisition furthers our strategic goal of becoming a fully integrated specialty plasma company,\u201d said Amir London, CEO of Kamada. \u201cWe are already actively engaged in the expansion of the hyperimmune plasma … <\/p>\n

Continue reading “Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S.”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-449269","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nKamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Transaction Furthers Kamada\u2019s Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company Kamada is Already Actively Engaged in the Expansion of the Center\u2019s Collection Capacity; Planning to Open Additional Plasma Collection Centers REHOVOT, Israel, March 03, 2021 (GLOBE NEWSWIRE) — Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today updated that it has completed the previously announced acquisition of the FDA licensed plasma collection center and certain related rights and assets from the privately-held Blood and Plasma Research, Inc (B&PR) of Beaumont, TX, USA. \u201cThis acquisition furthers our strategic goal of becoming a fully integrated specialty plasma company,\u201d said Amir London, CEO of Kamada. \u201cWe are already actively engaged in the expansion of the hyperimmune plasma … Continue reading "Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S."\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-03T12:03:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mjk3NSM0MDQ0NDk1IzIwMTcxNTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S.\",\"datePublished\":\"2021-03-03T12:03:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\\\/\"},\"wordCount\":862,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4Mjk3NSM0MDQ0NDk1IzIwMTcxNTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\\\/\",\"name\":\"Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4Mjk3NSM0MDQ0NDk1IzIwMTcxNTI=\",\"datePublished\":\"2021-03-03T12:03:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4Mjk3NSM0MDQ0NDk1IzIwMTcxNTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4Mjk3NSM0MDQ0NDk1IzIwMTcxNTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\/","og_locale":"en_US","og_type":"article","og_title":"Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S. - Market Newsdesk","og_description":"Transaction Furthers Kamada\u2019s Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company Kamada is Already Actively Engaged in the Expansion of the Center\u2019s Collection Capacity; Planning to Open Additional Plasma Collection Centers REHOVOT, Israel, March 03, 2021 (GLOBE NEWSWIRE) — Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today updated that it has completed the previously announced acquisition of the FDA licensed plasma collection center and certain related rights and assets from the privately-held Blood and Plasma Research, Inc (B&PR) of Beaumont, TX, USA. \u201cThis acquisition furthers our strategic goal of becoming a fully integrated specialty plasma company,\u201d said Amir London, CEO of Kamada. \u201cWe are already actively engaged in the expansion of the hyperimmune plasma … Continue reading \"Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-03T12:03:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mjk3NSM0MDQ0NDk1IzIwMTcxNTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S.","datePublished":"2021-03-03T12:03:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\/"},"wordCount":862,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mjk3NSM0MDQ0NDk1IzIwMTcxNTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\/","name":"Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mjk3NSM0MDQ0NDk1IzIwMTcxNTI=","datePublished":"2021-03-03T12:03:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mjk3NSM0MDQ0NDk1IzIwMTcxNTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4Mjk3NSM0MDQ0NDk1IzIwMTcxNTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kamada-announces-the-closing-of-the-acquisition-of-the-fda-licensed-plasma-collection-center-from-blood-and-plasma-research-inc-in-the-u-s\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/449269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=449269"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/449269\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=449269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=449269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=449269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}